by John Conrad | Dec 2, 2024 | iBIO News
The pharmaceutical industry faces a pivotal moment as political shifts introduce new dimensions of uncertainty into our operating environment. The recent election outcomes and potential leadership changes at key health agencies are reshaping the landscape for...
by John Conrad | Nov 14, 2024 | iBIO News
In a significant move to enhance science education across Illinois, the Illinois Biotechnology Innovation Organization (iBIO) has launched its innovative “LabShare” program. This groundbreaking program connects surplus laboratory equipment from iBIO member...
by John Conrad | Nov 13, 2024 | iBIO News
This month’s G2G report features 148 funding opportunities totaling over $500 million in non-dilutive funding for life sciences companies. Through iBIO’s G2G Consulting partnership, members have exclusive access to these comprehensive resources that help...
by John Conrad | Nov 5, 2024 | Policy News
Disclaimer: iBIO is a nonpartisan organization and does not endorse any candidate for public office. This article is provided for informational purposes only to help our members understand potential policy implications of election outcomes. As voters head to the polls...
by John Conrad | Oct 30, 2024 | iBIO News
The path to STEM careers often begins with early exposure and encouragement. For girls in underserved communities, access to engaging STEM education can be transformative, opening doors to future opportunities that might otherwise remain closed. iBIO’s STEMgirls...
by John Conrad | Oct 30, 2024 | Member News, NewsBrief
Pathos AI, a Chicago-based biotech startup, has secured $62 million in Series C funding to advance its AI-driven approach to drug development, according to a Tuesday press release. The funding news, also covered by Katherine Davis of Crain’s Chicago Business and...
by John Conrad | Oct 28, 2024 | Member News, NewsBrief
AbbVie announced today it will acquire Boston-based Aliada Therapeutics in a $1.4 billion cash deal, expanding its presence in neuroscience and Alzheimer’s disease research. The acquisition gives AbbVie access to Aliada’s novel blood-brain barrier crossing...
by John Conrad | Oct 28, 2024 | Member News, NewsBrief
Chicago-headquartered Iterum Therapeutics (Nasdaq: ITRM) has received U.S. Food and Drug Administration (FDA) approval for ORLYNVAH™ (sulopenem etzadroxil and probenecid) for the treatment of uncomplicated urinary tract infections (uUTIs) in adult women with limited...
by John Conrad | Oct 21, 2024 | iBIO News
Bristol Myers Squibb-sponsored kits will be distributed to 4th-8th graders at Frank W. Gunsaulus Scholastic Academy CHICAGO, IL – October 21, 2024 – The Illinois Biotechnology Innovation Organization (iBIO) is partnering with Bristol Myers Squibb (BMS) to...
by Monique Naleway | Oct 17, 2024 | STEM Heros
